Authors: GARDIN G FORNASIERO A ROMIEU G BUZZI F CHAUDRI HA LASSUS M

Citation: G. Gardin et al., LONG-DURATION OF RESPONSE WITH LETROZOLE 2.5 MG (FEMARA(R)) IN 2 TRIALS IN POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST-CANCER AFTER ANTIESTROGEN THERAPY, European journal of cancer, 34, 1998, pp. 46-46

Authors: GERSHANOVICH M CHAUDRI HA CAMPOS D LURIE H BONAVENTURA A JEFFREY M BUZZI F BODROGI I LUDWIG H REICHARDT P OHIGGINS N ROMIEU G FRIEDERICH P LASSUS M

Citation: M. Gershanovich et al., LETROZOLE, A NEW ORAL AROMATASE INHIBITOR - RANDOMIZED TRIAL COMPARING 2.5MG DAILY, 0.5MG DAILY AND AMINOGLUTETHIMIDE IN POSTMENOPAUSAL WOMEN WITH ADVANCED BREAST-CANCER, Annals of oncology, 9(6), 1998, pp. 639-645

Authors: BHATNAGAR A DOWSETT M SANTEN D SMITH I BOEHM R LONNING P TEDESCHI M LASSUS M MILLER B TOMINAGA T

Citation: A. Bhatnagar et al., PHARMACOLOGICAL PROFILE OF AN IDEAL AROMATASE INHIBITOR IN THE TREATMENT OF BREAST-CANCER - DISCUSSION OF SESSION 2, Breast cancer research and treatment, 49, 1998, pp. 73-77

Authors: BRUFMAN G COLAJORI E GHILEZAN N LASSUS M MARTONI A PEREVODCHIKOVA N TOSELLO C VIARO D ZIELINSKI C KRAINER M SALZER H SCHULLER J DITTRICH C SCHEITHAUER W ZAMAGNI C AMBROSINI G COLUCCI G GENTILINI P ZANIBONI A PACINI P BIANCO R MUSTACCHI G DAPRILE M DEMATTEIS A OLIVEIRA C JORDAAN J GUDGEON A VANZYL J RAKOWSKY E INBAR M RATH P COHEN Y SHANI A FRIED G HEGG R NETO AB BADER G BRAGA RF VITOC C PUERTO VML VALLE AE SALAZAR JD SANCHEZ JC VILLELA GM FOUNTZILAS G

Citation: G. Brufman et al., DOUBLING EPIRUBICIN DOSE INTENSITY (100 MG M(2) VERSUS 50 MG/M(2)) INTHE FEC REGIMEN SIGNIFICANTLY INCREASES RESPONSE RATES - AN INTERNATIONAL RANDOMIZED PHASE-III STUDY IN METASTATIC BREAST-CANCER/, Annals of oncology, 8(2), 1997, pp. 155-162

Authors: SESSA C PAGANI O ZURLO MG DEJONG J HOFMANN C LASSUS M MARRARI P BENEDETTI MS CAVALLI E

Citation: C. Sessa et al., PHASE-I STUDY OF THE NOVEL DISTAMYCIN DERIVATIVE TALLIMUSTINE (FCE-24517), Annals of oncology, 5(10), 1994, pp. 901-907